1616950-82-3

Upstream product

• 1266227-19-3 N-(5-bromopyridin-3-yl)-2-phenylacetamide 
• 76513-69-4 (2-trimethylethylsilylethoxy)methyl chloride 
• 319474-52-7 1-(4-methyl-piperazin-1-yl)benzene-2,3-diamine 
• 1616950-81-2 N-(5-(3-formyl-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazol-5-yl)pyridin-3-yl)-2-phenylacetamide 
• 74628-20-9 3-(4-methylpiperazin-1-yl)-2-nitroaniline 
• 109-01-3 1-methyl-piperazine 
• 1467098-45-8 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indazole-3-carbaldehyde 
• 59483-54-4 3-chloro-2-nitro-aniline 

Downstream Products

• 1616950-80-1 N-(5-(3-(4-(4-methylpiperazin-1-yl)-1H-benzo[d]imidazol-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-2-phenylacetamide 

Relevant academic research and scientific papers

3-(BENZOIMIDAZOL-2-YL)-INDAZOLE INHIBITORS OF THE WNT SIGNALING PATHWAY AND THERAPEUTIC USES THEREOF

Indazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, Alzheimer's disease, lung disease and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.